Evolus (EOLS) Non-Current Deffered Revenue (2017 - 2018)
Evolus (EOLS) reported Non-Current Deffered Revenue of $25000.0 for Q4 2018, down 34.21% on a YoY basis from $38000.0 in Q4 2017, and down 13.79% quarter-over-quarter from $29000.0 in Q3 2018.
Evolus (EOLS) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Evolus has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $25000.0 in Q4 2018.
- For the quarter ending Q4 2018, Non-Current Deffered Revenue fell 34.21% year-over-year to $25000.0; the trailing twelve-month figure through Dec 2018 stood at $25000.0 (down 34.21% YoY), and the FY2018 full-year result was $25000.0, down 34.21% from the prior year.
- Non-Current Deffered Revenue for Q4 2018 stood at $25000.0, down from $29000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $38000.0 in Q4 2017, with the low at $25000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Evolus | 437.40 Mn | 387.61 Mn | 48.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 25,000.00 |
| Sep 30, 2018 | 29,000.00 |
| Jun 30, 2018 | 32,000.00 |
| Mar 31, 2018 | 35,000.00 |
| Dec 31, 2017 | 38,000.00 |